Page 31 - Biological E News Today : Breaking News, Live Updates & Top Stories | Vimarsana

US to provide funds to Biological E for making 1 billion doses by 2022 The United States, through the DFC (Development Finance Corporation), will work with Biological E Ltd, to finance increased capacity to support Biological E's effort to produce at least 1 billion doses of COVID-19 vaccines by the end of 2022 PTI | March 13, 2021 | Updated 08:45 IST The US will provide financial assistance to support Indian drug-maker Biological E's effort to produce at least 1 billion doses of COVID-19 vaccines by the end of 2022, a document released by the White House on Friday after the Quad summit said...

US to provide financial assistance to Indian vaccine maker Biological E The Quad leaders decided to launch a mega vaccine initiative under which coronavirus vaccines will be produced in India for the Indo-Pacific region with financial assistance from the US and Japan, while Australia will contribute in logistical aspects.Premium 2 min read . Updated: 13 Mar 2021, 08:45 AM IST PTI US will work with Biological E Ltd to finance increased capacity to support production of at least 1 billion doses of COVID-19 vaccines by the end of 2022 Share Via Read Full Story NEW DELHI : The US will provide f...

March 13, 2021 Biological E Ltd's vaccine plant at Shamirpet× Announcement in line with Quad leaders decision to work together on vaccine production, distribution In a major boost to India’s vaccine production drive, the US International Development Finance Corporation (DFC), the country’s development bank, has announced that it will finance Indian manufacturer Biological E Ltd’s effort to produce at least 1 billion doses of Covid-19 vaccines by the end of 2022 which will also include Johnson & Johnson vaccines. This is in line with the Quad leaders’ decision on Friday to work toge...

India may have to wait for bridging trialJ&Js deal with Biological E is a global supply agreement and the company will be tapped to meet commitments in Europe and other parts of the world where the company has signed bilateral deals.

3,019,330.0 Three companies — Biological E, Dr Reddy’s Laboratories and Serum Institute of India — are preparing to submit data for approval of their Covid-19 vaccines or to start phase-3 trials, raising hopes of additional supplies for the country’s immunisation programme. Additionally, Bharat Biotech, which received emergency approval for its Covaxin vaccine that’s being used to immunise healthcare workers, will release its phase-3 efficacy data in the next two weeks, chairman Krishna Ella told ET at the BioAsia 2021 conference. Approval for Covaxin in the absence of efficacy data...